BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 20855960)

  • 41. S1, a novel pan-BH3 mimetic, induces apoptosis in Mcl-1-overexpressing cells through Bak.
    Song T; Chang X; Zhang Z; Liu Y; Shen X
    J Pharmacol Sci; 2012; 119(4):330-40. PubMed ID: 22814102
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Crosstalk among Bcl-2 family members in B-CLL: seliciclib acts via the Mcl-1/Noxa axis and gradual exhaustion of Bcl-2 protection.
    Hallaert DY; Spijker R; Jak M; Derks IA; Alves NL; Wensveen FM; de Boer JP; de Jong D; Green SR; van Oers MH; Eldering E
    Cell Death Differ; 2007 Nov; 14(11):1958-67. PubMed ID: 17703234
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer.
    Vallet S; Fan F; Malvestiti S; Pecherstorfer M; Sattler M; Schneeweiss A; Schulze-Bergkamen H; Opferman JT; Cardone MH; Jäger D; Podar K
    Breast Cancer Res Treat; 2019 Feb; 173(3):585-596. PubMed ID: 30374681
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis.
    Martínez-Paniagua MA; Baritaki S; Huerta-Yepez S; Ortiz-Navarrete VF; González-Bonilla C; Bonavida B; Vega MI
    Cell Cycle; 2011 Aug; 10(16):2792-805. PubMed ID: 21822052
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differential regulation of Bax and Bak by anti-apoptotic Bcl-2 family proteins Bcl-B and Mcl-1.
    Zhai D; Jin C; Huang Z; Satterthwait AC; Reed JC
    J Biol Chem; 2008 Apr; 283(15):9580-6. PubMed ID: 18178565
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pseudomonas exotoxin A-mediated apoptosis is Bak dependent and preceded by the degradation of Mcl-1.
    Du X; Youle RJ; FitzGerald DJ; Pastan I
    Mol Cell Biol; 2010 Jul; 30(14):3444-52. PubMed ID: 20457813
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.
    Zhou L; Zhang Y; Sampath D; Leverson J; Dai Y; Kmieciak M; Nguyen M; Orlowski RZ; Grant S
    Br J Cancer; 2018 Feb; 118(3):388-397. PubMed ID: 29241222
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MCL-1 inhibits BAX in the absence of MCL-1/BAX Interaction.
    Germain M; Milburn J; Duronio V
    J Biol Chem; 2008 Mar; 283(10):6384-92. PubMed ID: 18089567
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.
    Sung ES; Park KJ; Choi HJ; Kim CH; Kim YS
    Exp Cell Res; 2012 Aug; 318(13):1564-76. PubMed ID: 22513214
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression.
    Olberding KE; Wang X; Zhu Y; Pan J; Rai SN; Li C
    Cancer Biol Ther; 2010 Nov; 10(9):918-29. PubMed ID: 20818182
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pan-Bcl-2 inhibitor obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells.
    Koehler BC; Scherr AL; Lorenz S; Elssner C; Kautz N; Welte S; Jaeger D; Urbanik T; Schulze-Bergkamen H
    PLoS One; 2014; 9(9):e106571. PubMed ID: 25192188
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A novel BH3 mimetic S1 potently induces Bax/Bak-dependent apoptosis by targeting both Bcl-2 and Mcl-1.
    Zhang Z; Song T; Zhang T; Gao J; Wu G; An L; Du G
    Int J Cancer; 2011 Apr; 128(7):1724-35. PubMed ID: 20503275
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis.
    Wittmann S; Bali P; Donapaty S; Nimmanapalli R; Guo F; Yamaguchi H; Huang M; Jove R; Wang HG; Bhalla K
    Cancer Res; 2003 Jan; 63(1):93-9. PubMed ID: 12517783
    [TBL] [Abstract][Full Text] [Related]  

  • 54. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.
    Martin AP; Park MA; Mitchell C; Walker T; Rahmani M; Thorburn A; Häussinger D; Reinehr R; Grant S; Dent P
    Mol Pharmacol; 2009 Aug; 76(2):327-41. PubMed ID: 19483105
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytotoxicity induced by manipulation of signal transduction pathways is associated with down-regulation of Bcl-2 but not Mcl-1 in MCF-7 human breast cancer.
    Hu Y; Dragowska WH; Wallis A; Duronio V; Mayer L
    Breast Cancer Res Treat; 2001 Nov; 70(1):11-20. PubMed ID: 11767000
    [TBL] [Abstract][Full Text] [Related]  

  • 56. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells.
    Pérez-Galán P; Roué G; López-Guerra M; Nguyen M; Villamor N; Montserrat E; Shore GC; Campo E; Colomer D
    Leukemia; 2008 Sep; 22(9):1712-20. PubMed ID: 18596739
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.
    Merino D; Whittle JR; Vaillant F; Serrano A; Gong JN; Giner G; Maragno AL; Chanrion M; Schneider E; Pal B; Li X; Dewson G; Gräsel J; Liu K; Lalaoui N; Segal D; Herold MJ; Huang DCS; Smyth GK; Geneste O; Lessene G; Visvader JE; Lindeman GJ
    Sci Transl Med; 2017 Aug; 9(401):. PubMed ID: 28768804
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
    Witters LM; Witkoski A; Planas-Silva MD; Berger M; Viallet J; Lipton A
    Oncol Rep; 2007 Feb; 17(2):465-9. PubMed ID: 17203189
    [TBL] [Abstract][Full Text] [Related]  

  • 59. VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia.
    Samuel S; Tumilasci VF; Oliere S; Nguyên TL; Shamy A; Bell J; Hiscott J
    Mol Ther; 2010 Dec; 18(12):2094-103. PubMed ID: 20842105
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells.
    Hamed HA; Yamaguchi Y; Fisher PB; Grant S; Dent P
    J Cell Physiol; 2013 Oct; 228(10):1996-2005. PubMed ID: 23674352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.